Skip to Content
Search Menu

EADV 2026: Real-World Outcomes with Sonidegib and Cemiplimab in Advanced Cutaneous Carcinomas

How do sonidegib and cemiplimab perform in real-world clinical practice? Dr. Chiara Del Re, dermatologist at Magna Graecia University in Italy, shares findings from a single-center observational study, exploring efficacy, lesion reduction, and safety in patients with advanced cutaneous carcinomas presented at EADV 2026.
Chiara Del Re

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Nikolai Nguyen Loft

EADV 2026: Treatment With Semaglutide Lowers the Risk of Developing Psoriasis Compared to Liraglutide

/ Nikolai Loft
EADV26ObesityPsoriasisType 2-diabetes Play the Video 4:06
Kevin Jacobsen

EADV 2026: Non-Invasive Imaging and Transcriptomic Profiling of Basal Cell Carcinoma

/ Kevin Jacobsen
EADV26 Play the Video 4:06

EADV 2026: Climate Change Linked to Growing Skin Disease Burden, Particularly in Lower-Income Countries

/ Jan Andreasen
EADV26Skin disease
Dr. Reza Yazdanpanah

EADV 2026: Chronic Treatment-Resistant Folliculitis

/ Reza Yazdanpanah
EADV26 Play the Video 6:52
Ida Marie Nedergaard Thomsen

EADV 2026: Danish Study Highlights Lasting Benefits of Lebrikizumab in Atopic Dermatitis

/ Ida Marie Nedergaard Thomsen
Atopic dermatitisEADV26 Play the Video 2:42
Back to top